patent.fyi
Applications  /  US 2026/0355215
United States Patent Application Publication

US 2026/0355215 A1

Published
Nov 12, 2026
Filed
Jun 29, 2026
Earliest date on the face
Aug 4, 2020
Classification
A61K 31/5513
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Low concentration atropine drops

What ifWhat if atropine sulfate served as the active ingredient in an eye drop for slowing myopia progression?
Claim language“(+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof”

A sterile aqueous formulation contains 0.05% atropine sulfate by mass per volume. Topical dosing delivers atropine to ocular tissues, where it antagonizes muscarinic receptors, and serial optical biometry measures axial elongation.

1.1Pirenzepine in an ocular gel

What ifWhat if pirenzepine served as the active ingredient in a topical gel for slowing myopia progression?
Claim language“(+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof”

A 2% pirenzepine gel uses a water-swollen polymer to provide viscosity and retain the dose on the ocular surface. Pirenzepine leaves the gel and antagonizes muscarinic receptors, with preferential affinity for the M1 subtype.

1.1Optical correction with a lens

What ifWhat if a dual-focus soft contact lens supplied the myopia control effect through optical power?
Claim language“(+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof”

A central distance zone corrects the wearer's refractive error. Concentric treatment zones add positive power to produce simultaneous myopic defocus during daytime wear.

1.2Equal proportions of both enantiomers

What ifWhat if the formulation contained the positive and negative enantiomers in a one-to-one molar ratio?
Claim language“substantially free of (−)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof”

The formulation retains both enantiomers as active-material constituents and sets the dose using the measured concentration of the positive enantiomer. Chiral liquid chromatography resolves the two constituents and verifies their ratio.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Hydrochloride salt replaces the free base

The hydrochloride salt of the (+) enantiomer serves as the active ingredient in place of the free base. The formulation uses the salt assay and the molecular weights of the salt and free base to calculate the mass that delivers the target amount of the active moiety. A chiral chromatographic assay measures the (−) enantiomer in the salt lot and in the finished composition.

Parameter or scale variation

Pilot batches at two fill scales

A pilot fill study uses 1 L and 10 L batches with the same formulation and target fill volume. Each batch feeds a filling pump through a closed transfer line. Samples from the first, middle and last 10 filled units at each scale provide fill-mass measurements. Pooled samples from each position provide measurements of active content and (−) enantiomer content.

Combination with existing systems

Dispensing records linked to ocular biometry

A clinical dispensing system links each container lot to the participant identifier and dispensing date in a study record. An optical biometer supplies the axial length, eye laterality and timestamp for each visit. The study system joins the records by participant identifier and groups measurements by eye. It displays change from baseline alongside the dispensing dates and lot identifiers.

Temperature logging for packaged stability samples

A stability monitoring system stores sealed units of the composition in temperature-controlled chambers with calibrated data loggers. Each unit identifier links the formulation lot, packaging lot and planned withdrawal date to a chamber identifier. At each withdrawal, the laboratory measures active content and (−) enantiomer content by chiral chromatography. The system aligns each assay result with the chamber temperature history for that unit.

Automated or data-driven variant

Automated review of chiral assay data

Chromatography software assigns the (+) and (−) peaks using retention windows established with separate enantiomer reference solutions. A spiked control confirms peak identity and checks separation before the software processes the batch samples. The software converts the (−) peak area to concentration using a calibration curve and reports results below the quantitation limit as such. It flags failed controls and results above the specified impurity limit for analyst review.

Specific version of a part

Hydrochloride salt in solution

The positive enantiomer is present as a hydrochloride salt in an aqueous ophthalmic formulation. The formulation records the active concentration as mass of the positive free base per milliliter.

Free base in a suspension

Micronized particles of the positive free base disperse in a sterile aqueous vehicle containing a wetting agent and a viscosity modifier. Shaking redistributes settled particles before dispensing.

Chromatographic control of enantiomer content

Preparative chiral chromatography separates the enantiomers, and the collected positive-enantiomer fraction supplies the formulation. An analytical chiral assay measures residual negative enantiomer in the finished composition against a reference solution.

Cite aspatent.fyi, US 2026/0355215 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355215/, SHA-256 ff1b78a612121e35ba6d3ffea206f09ccfc2ddae0eb782944d73498e1e32a4ac
First published
Permanent addresshttps://patent.fyi/US20260355215/
Content fingerprint (SHA-256)ff1b78a612121e35ba6d3ffea206f09ccfc2ddae0eb782944d73498e1e32a4ac
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi